News Headlines Article

FDA panel recommends agency reject NeurogesX HIV pain patch
San Francisco Business Times

An FDA advisory panel unanimously recommended Thursday that the agency reject an HIV pain patch from NeurogesX Inc. not be approved. Qutenza, the patch from the San Mateo-based company (NASDAQ: NGSX), already is used for pain related to shingles, but NeurogesX is seeking Food and Drug Administration approval for its use in nerve damage associated with the AIDS virus.

Commands